APOC3 and coronary artery disorder: Studies combining human genetics and epidemiology reveal that heterozygous missense variants in APOC3 are associated with a 44% decrease in non-fasting TGs levels and a significant reduction in the risk of CHD and ischemic vascular disease incidents [129].